New hope for tough breast cancer: SKB264 shows promise in Late-Stage trial
NCT ID NCT05347134
First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 22 times
Summary
This phase 3 study tests a new drug, SKB264, against standard treatments for people with advanced triple-negative breast cancer that has not responded to at least two prior therapies. The main goal is to see if SKB264 can delay cancer growth. About 254 participants are being studied to compare outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, 100021, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
Conditions
Explore the condition pages connected to this study.